This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and Statens Serum Institut to evaluate and transition the Lawrence Livermore Microarray Detection Array (LLMDA) analysis software package, the Composite Likelihood Maximization method (CLiMax) to the SSI. The SSI is a public enterprise under the Danish Ministry of Health that operates a microbiology reference laboratory for the Danish population and analyzes tens to thousands of human clinical samples annually. SSI has been collaborating with the LLNL team for several years to use the LLMDA to analyze viral and bacterial infections from human clinical samples. The collaboration has resulted in two joint publications thus far, describing improvements to LLMDA sample preparation, and the utility of the LLMDA for detecting emerging viruses in clinical samples. Under our previous collaboration, SSI has performed LLMDA experiments at their facility and then transferred the raw LLMDA data to LLNL for analysis. SSI had purchased LLMDA microarrays directly from the manufacturer, Roche NimbleGen. The main purpose of the current collaboration was to adapt the CLiMax analysis software so that it could run on a computer located at SSI. Additional effort was budgeted for LLNL staff to assist SSI with the transition and the operation of the software. The primary deliverable is the CLiMax software, installed on a computer at SSI.